SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Progress toward the Valaris merger including reported final Brazilian regulatory approvalhas renewed attention on RIG, with bullish traders citing the combined offshore fleet, contract backlog and elevated short interest as potential tailwinds. Others remain wary of share dilution, debt and the stocks muted reaction to positive developments; merger completion is still pending.

Starbucks Corp. engages in the production, marketing, and retailing of specialty coffee. It operates through the following segments: North America, International, and Channel Development. The North America segment focuses on the United States and Canada. The International segment is involved in China, Japan, Asia Pacific, Europe, Middle East, Africa, Latin America, and Caribbean. The Channel Development segment includes roasted whole bean and ground coffees, Seattle’s Best Coffee, and Teavana-branded single-serve products. The company was founded by Jerry Baldwin and Howard D. Schultz on November 4, 1985, and is headquartered in Seattle, WA.

Starbucks Corp.

Starbucks Corp

Starbucks quarterly results and outlook are driving discussion: earnings and comparable sales beat expectations, but revenue missed, with the China restructuring weighing on reported sales, and shares declined. Bulls point to improving U.S. traffic and turnaround progress, while bears focus on the revenue miss, soft reported growth outlook and valuation.

Marathon Petroleum Corp. engages in the refining, marketing, and transportation of petroleum products. It operates through the Refining and Marketing, and Midstream segments. The Refining and Marketing segment includes refining crude oil and other feedstocks, purchasing ethanol, and refined products for resale and distribution of refined products. The Midstream segment refers to transportation, storing, distribution, and marketing of crude oil and refined products. The company was founded in 1887 and is headquartered in Findlay, OH.

Marathon Petroleum Corp

MPC is drawing attention amid a powerful rally in refiners, with traders pointing to elevated crack spreads and tight refined-fuel supplies tied to geopolitical disruptions as support for refinery margins. The community is split between bullish momentum and expectations of a pullback, with some questioning whether unusually strong margins can last after the sectors sharp run.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could decline sharply in 2027 has fueled concern about pricing and revenue for CorMedixs flagship product, alongside the steep selloff. Traders are divided over whether DaVitas preliminary, company-specific modeling signals a lasting commercial headwind or overstates the risk given uncertainty around future reimbursement and product adoption.

NANO Nuclear Energy, Inc. is a microreactor and nuclear technology company, which provides supply energy services. Its products in technical development are ZEUS, a solid core battery reactor, and ODIN, a low-pressure coolant reactor. The company is founded by Jiang Yu in February, 2022 and is headquartered in New York, NY.

Nano Nuclear Energy Inc.

NNE is drawing attention amid a steep selloff shared by other speculative nuclear and small-modular-reactor stocks, with traders debating whether the decline reflects sector-wide weakness or concerns about the companys early-stage, pre-revenue business and execution risks. Some are buying the dip on the long-term nuclear-power and AI data-center demand thesis, while others remain bearish after the sustained losses.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX is drawing attention as shares reach fresh 52-week highs ahead of an expected, but unconfirmed, Q3 report, with traders watching BRIUMVIs sales momentum and whether results support the rally. Buyout and short-squeeze speculation is adding to bullish sentiment, though some traders see earnings and the commercial growth storynot an acquisitionas the main driver.

Fundrise Innovation Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is drawing attention as a proxy for private AI holdings, especially amid speculation about a potential Anthropic IPO. Bulls see the listing as a catalyst, while bears question the funds premium to NAV and point to dilution and claims that it reduced its Anthropic stake.

Kimberly-Clark Corp. engages in the manufacture and marketing of products made from natural or synthetic fibers. It operates through North America and International Personal Care segments. The North America segment consists of products encompassing each of daily-need categories across consumer and professional channels including disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear, facial and bathroom tissue, paper towels, napkins, wipers, tissue, towels, soaps and sanitizers and other related products. The International Personal Care segment consists of three core categories: Baby & Child Care, Adult Care, and Feminine Care, including disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear and other related products. The company was founded by John A. Kimberly, Havilah Babcock, Charles B. Clark, and Frank C. Shattuck in 1872 and is headquartered in Dallas, TX.

Kimberly-Clark Corp.

Kimberly-Clark is drawing attention after preliminary Q3 results topped expectations and the company reaffirmed its outlook; traders also point to easing Huggies-related concerns in China and progress toward financing and regulatory approval for the Kenvue acquisition. Reactions are constructive around defensive-staples demand and the mergers potential, though some remain wary of deal execution and the stocks recent weakness.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

AEHR is drawing attention for a sharp selloff amid concerns about its rich valuation, execution, and weakening price action. Traders are debating whether the decline is overdone ahead of earnings, with bulls pointing to AI chip-testing demand and expected growth while bears question whether orders and guidance will justify expectations.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarins first profitable quarter in more than two years and debt-free balance sheet are drawing attention, but traders are weighing that progress against declining revenue and a weak share-price reaction. Discussion also centers on EMT2s mixed Phase 3 resultsa positive overall-survival signal despite missing the primary progression-free-survival endpointand speculation over whether the Barclays strategic review will lead to a transaction or capital return.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc Disease at the North American Spine Society 2026 Annual Meeting

FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc Disease at the North American Spine Society 2026 Annual Meeting FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc...

FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs

FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated...

FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body

FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the BodyPR NewswireHOUSTON, Oct. 7, 2026New approach...

FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity

FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic ActivityPR NewswireHOUSTON, Sept. 29, 2026 Newly Granted Patent Covers Methods of Augmenting...

FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer

FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific OfficerPR NewswireHOUSTON, Sept. 17, 2026 HOUSTON, Sept. 17, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq...

FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing

FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing PR Newswire HOUSTON, Sept. 3, 2026 Newly Issued Patent Covers Topical...

FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media

FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media PR Newswire HOUSTON, Sept. 1...

FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial PR Newswire HOUSTON, Aug. 27, 2026 HOUSTON, Aug. 27, 2026 /PRNewswire...

FibroBiologics Regains Compliance with Nasdaq Trading Rules

FibroBiologics Regains Compliance with Nasdaq Trading Rules FibroBiologics Regains Compliance with Nasdaq Trading Rules PR Newswire HOUSTON, Aug. 26, 2026 HOUSTON, Aug. 26, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology...

FibroBiologics Appoints Leigh Steinberg to Board of Directors

FibroBiologics Appoints Leigh Steinberg to Board of Directors FibroBiologics Appoints Leigh Steinberg to Board of Directors PR Newswire HOUSTON, Aug. 24, 2026 Legendary Sports Agent, Attorney, and Longtime Advocate for Human Longevity and Brain Health Joins BoardHOUSTON, Aug. 24, 2026 /PRNewswire...

FibroBiologics, Inc. engages in the development and commercialization of cell therapies. It focuses on treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The firm’s product pipeline includes CybroCell, CYMS101, CYWC628, TCB190, and CYTER915. The company was founded by Peter O’Heeron on April 8, 2021 and is headquartered in Houston, TX.

FibroBiologics Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

🚀 $FBLG — FibroBiologics: A Regenerative Medicine Company Worth Watching

Recent preclinical research into spinal disc regeneration highlights the potential of fibroblast-based therapies.

The company is also developing treatments for chronic wounds and other serious conditions.

Could FBLG become a major player in regenerative medicine?

My personal long-term bull-case target is €200 per share, but this is highly speculative and not supported by a validated valuation model.

Clinical results, financing, dilution and regulatory approvals will determine the outcome.

High risk. Significant scientific potential.

#FBLG #Biotech #RegenerativeMedicine

Biotechff

$FBLG I got a funny feeling could be a pump and dump type deal going on here with the way the action is
Invest at your own diligence.Just an opinion not advice!

Feed

News

Sentiment

Earnings

Fundamentals

Info

FBLG FibroBiologics Inc

Fundamentals

Latest FBLG News